56700-70-0

Basic information

• Product Name: 3-(BOC-AMINO)PYRIDINE
• Synonyms: TERT-BUTYL PYRIDIN-3-YLCARBAMATE;3-(BOC-AMINO)PYRIDINE;3-TERT-BUTOXYCARBONYLAMINOPYRIDINE;Carbamic acid, 3-pyridinyl-, 1,1-dimethylethyl ester (9CI);tert-butyl N-(pyridin-3-yl)carbaMate;3-(Boc-aMino)pyridine 97%;BOC-3-Amino pyridine
• CAS NO: 56700-70-0
• Molecular Formula: C₁₀H₁₄N₂O₂
• Molecular Weight: 194.23
• Product Categories: N-BOC;Heterocycles;C9 to C46;Heterocyclic Building Blocks;Pyridines
• Mol File: 56700-70-0.mol
• Article Data: 36

Chemical Properties

• Melting Point: 116-120 °C(lit.)
• Boiling Point: 252.743 °C at 760 mmHg
• Flash Point: 106.656 °C
• Appearance: /
• Density: 1.131
• Vapor Pressure: 0.019mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 12.93±0.70(Predicted)
• CAS DataBase Reference: 3-(BOC-AMINO)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(BOC-AMINO)PYRIDINE(56700-70-0)
• EPA Substance Registry System: 3-(BOC-AMINO)PYRIDINE(56700-70-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 56700-70-0(Hazardous Substances Data)

Usage

General Description

3-(BOC-AMINO)PYRIDINE is a chemical compound with the molecular formula C12H16N2O2. It is a derivative of pyridine and contains a BOC (tert-butoxycarbonyl) protected amino group. 3-(BOC-AMINO)PYRIDINE is commonly used as a building block in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. The BOC protecting group can be selectively removed under mild conditions, allowing for further functionalization of the amino group. 3-(BOC-AMINO)PYRIDINE is a versatile and valuable reagent in chemical manufacturing and research.

InChI:InChI=1/C10H14N2O2/c1-10(2,3)14-9(13)12-8-5-4-6-11-7-8/h4-7H,1-3H3,(H,12,13)

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 626-60-8 3-Chloropyridine 
• 4248-19-5 tert-butyl carbazate 
• 59-67-6 nicotinic acid 
• 75-65-0 tert-butyl alcohol 
• 34619-03-9 tert-butyldicarbonate 
• 626-55-1 3-Bromopyridine 
• 98-92-0 nicotinamide 
• 4013-72-3 nicotinoyl azide 
• 22236-96-0 3-N-formylaminopyridine 

Downstream Products

• 1371621-93-0 (R)-N-(4-(5-cyclopentyl-4-ethyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)pyridin-3-yl)benzamide 
• 883107-62-8 2,6-dichloro-3-amino-4-pyridinecarboxylic acid methyl ester 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 55279-30-6 methyl 3-aminoisonicotinate 
• 58484-01-8 3-amino-2,6-dichloroisonicotinic acid 
• 52834-10-3 3-Amino-2,6-dibromoisonicotinsaeure 
• 92635-33-1 1H-Pyrrolo[2,3-c]pyridine-2,3-dione 
• 1354621-59-2 C₁₄H₂₂N₂ 
• 1092578-48-7 tofacitinib 
• 96721-84-5 tert-butyl (6-nitropyridin-3-yl)carbamate 
• 1527743-14-1 C₁₂H₁₀ClFN₂ 

Relevant articles and documents

Synthesis of azacridone A

The first total synthesis of the only known naturally occurring azaacridone alkaloid (1) has been achieved in 10 steps from phloroglucinol. A variety of ortholithiation reactions are described, and a method for overcoming the originally unfavorable regiochemistry of one of them is provided.

NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS

The present invention provides novel poly(ADP-ribose) polymerase (PARP) inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods for the treatment, prevention and/or amelioration of PARP mediated diseases or disorders using them. In particular, the compounds described herein are useful for the treatment of carcinoma of the breast, ovarian cancer, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, pancreatic cancer and stomach cancer.

MODULATORS OF P97 AAA ATPASE ACTIVITY

The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by inhibition or modulation of p97.